We are live on ! Find out more
ALIM

Alimera Sciences

Delisted

ALIM was delisted on the 13th of September, 2024.

49 hedge funds and large institutions have $33.8M invested in Alimera Sciences in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

9% less funds holding

Funds holding: 5449 (-5)

35% less capital invested

Capital invested by funds: $51.9M → $33.8M (-$18.1M)

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14

58% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 19

Holders
49
Holders Change
-5
Holders Change %
-9.26%
% of All Funds
1.31%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
9
Increased
8
Reduced
19
Closed
14
Calls
Puts
Net Calls
Net Calls Change

ALIM Hedge Fund Activity: Q2 2016 in Review

49 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Alimera Sciences (ALIM) for Q2 2016, worth a combined $33.8M — down 35% from $51.9M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of ALIM and 9 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 8 added.

The largest buyer was J. Goldman & Co, adding an estimated $3.13M. The largest seller was OrbiMed, cutting an estimated $2.22M.

  • 49 institutional investors held Alimera Sciences (ALIM) as of Q2 2016, down from 54 in Q1 2016.
  • Funds reported $33.8M of Alimera Sciences stock for Q2 2016, down 35% quarter-over-quarter.
  • 9 funds opened new Alimera Sciences positions in Q2 2016 and 14 closed out, a net change of -5 holders.
  • The largest Alimera Sciences buyer in Q2 2016 was J. Goldman & Co, an estimated $3.13M added.
  • The largest Alimera Sciences seller in Q2 2016 was OrbiMed, an estimated $2.22M sold.

Based on aggregated 13F filings for Q2 2016.